Immunotherapy

Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma

Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma

By

Immunotherapy regimens FDA-approved for the treatment of melanoma may also be an option for a rare and aggressive form of papillary thyroid cancer.

Evolving Education Initiative Keeps Nurses Up-to-Date on CAR T Cell Therapy Best Practices

Evolving Education Initiative Keeps Nurses Up-to-Date on CAR T Cell Therapy Best Practices

By

A multidisciplinary education initiative was instrumental in preparing nursing and clinical staff for the challenges of managing care and follow-up of patients undergoing CAR-T therapy.

Checkpoint Inhibitors Appear Safe for Pediatric Cancer Patients

Checkpoint Inhibitors Appear Safe for Pediatric Cancer Patients

By

The medications so far show little efficacy in children with cancer, but new studies may provide clues to how to change this, pediatric oncologist says.

Adjuvant + Neoadjuvant Pembrolizumab Safe in Patients Undergoing HNSCC Surgery

Adjuvant + Neoadjuvant Pembrolizumab Safe in Patients Undergoing HNSCC Surgery

By

Study also provides evidence supporting an anti-tumor effect associated with a single preoperative dose of pembrolizumab.

Pediatric Acute Lymphoblastic Leukemia Extramedullary Relapse Responds to CAR-T

Pediatric Acute Lymphoblastic Leukemia Extramedullary Relapse Responds to CAR-T

By

Children with extramedullary relapse of CD19+ acute lymphoblastic leukemia experienced a potent and durable response to the immunotherapy.

Autologous T-Cell Therapy Promising in Advanced Sarcoma

Autologous T-Cell Therapy Promising in Advanced Sarcoma

By

After lymphodepletion in patients with advanced HER2+ sarcoma, T cells expanded in 5 of 6 patients who received infusions of HER2-CAR T cells.

Biopolymer Delivery of Synergistic Immunotherapy Could Improve Efficacy

Biopolymer Delivery of Synergistic Immunotherapy Could Improve Efficacy

By

Biopolymer codelivery of CAR T cells and stimulator of IFN genes directly to the surface of solid tumors more effectively reduced tumor size.

Influenza Vaccination Increases Toxicity in PD-1/PD-L1 Immunotherapy Blockade for Lung Cancer

Influenza Vaccination Increases Toxicity in PD-1/PD-L1 Immunotherapy Blockade for Lung Cancer

By

Seasonal influenza vaccination was associated with increased rates of immunologic toxicity in patients with lung cancer receiving PD-1/PD-L1 immunotherapy blockade.

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

By

The oncology nurses' role in monitoring and early recognition of the signs and symptoms of CAR T-cell toxicities is significant considering the potential severity of these adverse effects.

Nursing and Patient Education on Immunotherapy-related Adverse Events

Nursing and Patient Education on Immunotherapy-related Adverse Events

By

The unique adverse events related to treatment with immunotherapy require a proactive approach in the assessment of side effects and patient education.

Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab

Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab

By

A significantly higher 5-year survival rate was seen in a small subset of patients with NSCLC treated with nivolumab.

Continuing Nivolumab After Progression of Head and Neck Cancer May Improve Survival

Continuing Nivolumab After Progression of Head and Neck Cancer May Improve Survival

By

Continuing immunotherapy after disease progression extends survival for some patients with head and neck cancer.

Prostate Cancer Response to Immunotherapy Improved With Combination Therapy

Prostate Cancer Response to Immunotherapy Improved With Combination Therapy

By

Immunotherapy alone is not effective in prostate cancer; however, combining it with PD-1/PD-L1 and VISTA inhibitors is effective.

Research Shows iPS-ML/IFN-β Migrates to, Penetrate Liver Cancer Tumors

Research Shows iPS-ML/IFN-β Migrates to, Penetrate Liver Cancer Tumors

By

Decreased liver tumor growth and improved survival in a mouse model were noted after injecting iPS-ML/IFN-β.

Pembrolizumab May Help Combat Mesothelioma

Pembrolizumab May Help Combat Mesothelioma

By

Checkpoint inhibitor pembrolizumab appears well-tolerated with antitumor activity in patients with malignant pleural mesothelioma.

Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma

Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma

By

Whole-exome sequencing of tumor biopsies explain low response rate to immunotherapy in metastatic melanoma.

Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer

Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer

By

Cabozantinib activated innate immunity and completely eradicated prostate cancer in a study using a mouse model.

Regorafenib Improves Quality-adjusted Survival in Sarcoma

Regorafenib Improves Quality-adjusted Survival in Sarcoma

By

In patients with soft tissue sarcoma pretreated with doxorubicin, treatment with regorafenib significantly reduced the risk of progression symptoms or toxicity.

Immunosuppressor Inhibits Metabolic Pathway in Breast Cancer, Kills Cancer Cells

Immunosuppressor Inhibits Metabolic Pathway in Breast Cancer, Kills Cancer Cells

By

Leflunomide, an immunosuppressor FDA-approved for rheumatoid arthritis, is effective against breast cancer in mouse study.

PI3K/mTOR Inhibitor Demonstrates Efficacy in Some Uterine Sarcomas

PI3K/mTOR Inhibitor Demonstrates Efficacy in Some Uterine Sarcomas

By

A new generation dual PI3K/mTOR inhibitor shows promise in treating leiomyosarcomas with the protein P-S6S240.

Dabrafenib + Trametinib Rechallenge Active in Pretreated Melanoma

Dabrafenib + Trametinib Rechallenge Active in Pretreated Melanoma

By

Rechallenge with dabrafenib plus trametinib demonstrated antitumor activity in patients who had previously progressed on BRAF inhibitor therapy.

Patients With HER2-enriched Subtype Benefit Most from Dual HER2 Blockade

Patients With HER2-enriched Subtype Benefit Most from Dual HER2 Blockade

By

HER-2 enriched subtype predicts for HER2 blockade benefit with lapatinib and trastuzumab

Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated

Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated

By

Researchers sought to conduct a cost-effectiveness analysis of immunotherapy for patients with advanced melanoma.

1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer

1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer

By

Adjuvant trastuzumab following chemotherapy significantly improves long-term disease-free survival in women with HER2-positive early breast cancer, according to study data.

Immunotherapy and the Future of Prostate Cancer Treatment

Immunotherapy and the Future of Prostate Cancer Treatment

By

Despite early failures, there may be a role for single-agent and combination immunotherapy for patients with prostate cancer.

Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

By

In a study seeking new therapies to improve outcomes for patients with relapsed or refractory CLL, researchers investigated the impact on progression-free survival of adding idelalisib to bendamustine plus rituximab.

Attaching an Anticancer Payload to Platelets Shows Promise Against Postsurgical Recurrence

Attaching an Anticancer Payload to Platelets Shows Promise Against Postsurgical Recurrence

By

Researchers develop novel strategy for delivering immunotherapy agents to tumor surgical sites to eradicate tumor cells left behind after resection and reduce risk of recurrence.

Addition of Bevacizumab to Chemo Improves PFS in Extensive SCLC

Addition of Bevacizumab to Chemo Improves PFS in Extensive SCLC

By

The addition of bevacizumab to first-line treatment with cisplatin plus etoposide improved PFS, but not OS, with an acceptable toxicity profile in patients with extensive-disease SCLC.

New Targeted Therapy with a Double-Pronged Approach

New Targeted Therapy with a Double-Pronged Approach

By

A new targeted therapy approach may attack cancer on two fronts, boosting anti-tumor immune responses while also directly killing tumor cells .

New Use of an Old Drug Could Address Cancer Metastasis

New Use of an Old Drug Could Address Cancer Metastasis

By

CDK 4/6 inhibitors, currently approved for the treatment of estrogen-positive breast cancer, were found to inhibit metastasis in triple-negative breast

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs